BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,090 filers reported holding BAXTER INTL INC in Q2 2021. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $50,116 | +12.3% | 1,100 | 0.0% | 0.04% | +11.1% |
| Q1 2023 | $44,616 | +79571.4% | 1,100 | 0.0% | 0.04% | -14.3% |
| Q4 2022 | $56 | -99.9% | 1,100 | 0.0% | 0.04% | -8.7% |
| Q3 2022 | $59,000 | -16.9% | 1,100 | 0.0% | 0.05% | -4.2% |
| Q2 2022 | $71,000 | -16.5% | 1,100 | 0.0% | 0.05% | -5.9% |
| Q1 2022 | $85,000 | -9.6% | 1,100 | 0.0% | 0.05% | -10.5% |
| Q4 2021 | $94,000 | +6.8% | 1,100 | 0.0% | 0.06% | -3.4% |
| Q3 2021 | $88,000 | -1.1% | 1,100 | 0.0% | 0.06% | -3.3% |
| Q2 2021 | $89,000 | -4.3% | 1,100 | 0.0% | 0.06% | -14.1% |
| Q1 2021 | $93,000 | +5.7% | 1,100 | 0.0% | 0.07% | -6.6% |
| Q4 2020 | $88,000 | 0.0% | 1,100 | 0.0% | 0.08% | -9.5% |
| Q3 2020 | $88,000 | -11.1% | 1,100 | -3.9% | 0.08% | -21.5% |
| Q2 2020 | $99,000 | +6.5% | 1,145 | 0.0% | 0.11% | -8.5% |
| Q1 2020 | $93,000 | -3.1% | 1,145 | 0.0% | 0.12% | +23.2% |
| Q4 2019 | $96,000 | -5.0% | 1,145 | 0.0% | 0.10% | -2.1% |
| Q3 2019 | $101,000 | +5.2% | 1,145 | 0.0% | 0.10% | +7.8% |
| Q2 2019 | $96,000 | +7.9% | 1,145 | +4.1% | 0.09% | +5.9% |
| Q1 2019 | $89,000 | -23.3% | 1,100 | -31.2% | 0.08% | -24.8% |
| Q4 2018 | $116,000 | – | 1,600 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
| THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
| SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
| Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
| 13D Management LLC | 194,807 | $11,794,000 | 4.18% |
| Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
| Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
| Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
| PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |